Erenumab

Drug Profile

Erenumab

Alternative Names: AMG 334; Calcitonin gene-related peptide receptor antagonist monoclonal antibody - Amgen; CGRP receptor antagonist monoclonal antibody - Amgen

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Novartis
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine
  • Phase II Angina pectoris
  • No development reported Hot flashes

Most Recent Events

  • 16 Nov 2016 Safety and efficacy data from the phase III STRIVE trial in Migraine (Prevention) released by Amgen
  • 16 Nov 2016 Amgen completes enrolment in the phase III STRIVE clinical trials in Migraine (Prevention) in Czech Republic, United Kingdom, Turkey, Slovakia, Netherlands, Belgium, Poland, Canada, USA, Austria, Finland, Germany, Sweden, Hungary before November 2016 (NCT02456740)
  • 31 Oct 2016 Novartis initiates enrolment in the phase III LIBERTY trial in Migraine (Prevention) in Czech Republic, Finland, and Denmark (EudraCT2016-002211-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top